Cite
HARVARD Citation
Price, T. et al. (n.d.). 403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A245. [Online].